Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

• Surviving Cancer, Lacking Support: The Hidden Burden of Modern Radiation Oncology in the Treatment of Oligometastatic Disease

  2026 Cancers article Medicine Cancer survivorship and care Open access

  0

  citations
• Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial

  2026 The Lancet article Medicine Renal cell carcinoma treatment

  3

  citations
• REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer

  2025 Nature Communications article Medicine Pancreatic and Hepatic Oncology Research Open access

  10

  citations
• Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors

  2025 Nature Reviews Nephrology review Medicine Cancer Immunotherapy and Biomarkers

  40

  citations
• A Systematic Evaluation of the Dosing Regimens for Approved Targeted Therapies and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma From a Project OPTIMUS Perspective

  2025 The Journal of Clinical Pharmacology article Medicine Renal cell carcinoma treatment Open access

  1

  citations
• Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma

  2024 Cancer Immunology Immunotherapy article Medicine Cancer Immunotherapy and Biomarkers Open access

  6

  citations
• Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade

  2022 Science Immunology article Medicine Cancer Immunotherapy and Biomarkers

  42

  citations
• Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study

  2022 Journal of Geriatric Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access

  9

  citations
• Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands

  2022 Frontiers in Pharmacology article Medicine Renal cell carcinoma treatment Open access

  18

  citations
• Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: an observational study

  2021 Journal of Geriatric Oncology article Medicine Cancer Immunotherapy and Biomarkers

  1

  citations
• Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

  2021 Cancers article Medicine Medical Imaging Techniques and Applications Open access

  15

  citations
• Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study

  2021 PLoS ONE article Medicine Acute Kidney Injury Research Open access

  52

  citations
• Reclassification of Kidney Clear Cell Carcinoma Based on Immune Cell Gene-Related DNA CpG Pairs

  2021 Biomedicines article Biochemistry, Genetics and Molecular Biology Epigenetics and DNA Methylation Open access

  3

  citations
• Preclinical development and characterisation of 99mTc-NM-01 for SPECT/CT imaging of human PD-L1.

  2021 PubMed article Medicine Radiopharmaceutical Chemistry and Applications Open access

  12

  citations
• Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers

  2020 Clinical Genitourinary Cancer article Medicine Renal cell carcinoma treatment Open access

  25

  citations
• Genetic Screening for Novel Regulators of Immune Checkpoint Molecules

  2020 Trends in Immunology review Medicine Cancer Immunotherapy and Biomarkers

  5

  citations
• An Electronic Health Record Text Mining Tool to Collect Real‐World Drug Treatment Outcomes: A Validation Study in Patients With Metastatic Renal Cell Carcinoma

  2020 Clinical Pharmacology & Therapeutics article Health Professions Electronic Health Records Systems Open access

  48

  citations
• Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma

  2020 Clinical Genitourinary Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access

  13

  citations

18 results